Lyell Immunopharma, Inc. (LYEL)
D
Pipeline Grade
Financial Position (from SEC Filings)
$92.4M
Cash & Equivalents
$38.5M
Quarterly Burn Rate
7 mo
Est. Cash Runway
$350M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07188558 | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | PHASE3 | Recruiting | 400 |
| NCT05826535 | Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma | PHASE2 | Recruiting | 270 |
| NCT05319314 | LYL273 for Patients With Relapsed or Refractory mCRC | PHASE2 | Recruiting | 155 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.